TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）
Status:
Not yet recruiting
Trial end date:
2023-12-25
Target enrollment:
Participant gender:
Summary
In this study,189 adult migraine patients aged 18-65 years (diagnosed with migraine without
aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate
the efficacy, safety and tolerability of Tizanidine Hydrochloride in preventing migraine
attacks in episodic migraine in adults.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University